samedan logo
 
 
 
spacer
home > pmps > summer 2020 > achieving zero defects in a pandemic
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Achieving Zero Defects in a Pandemic

As the COVID-19 pandemic continues to unfold, the industry is working tirelessly to identify an effective treatment and vaccine. Amid the pressure to produce a vaccine in such a short time frame, there is also the pressure to ensure no valuable time and resources are wasted. Naturally, treatments that are being considered are large molecule drugs, which require manufacturers to address challenges with achieving zero defects and silicone contamination stemming from packaging and delivery.

Drug manufacturers have always aimed to minimise time to market while also protecting injectables against contamination. However, the challenges COVID-19 has posed to global supply chains have placed even greater emphasis on this goal. According to an FDA study, developing a new medicine takes on average 10 years and costs $2.6 billion from discovery through approval. These are high stakes, so it is essential to utilise every available tool in creating an uninterrupted transition from the development stage to production.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Massimo Mainetti holds a Master's degree in Business Administration from the University of Milan, Italy. He started his career in a finance firm in London. A few years later, in 2003, he joined Panasonic Industrial Europe as Key Account Manager and then moved to a Distribution Manager role. In 2008, Massimo assumed the position of Strategic Key Account Manager at Becton & Dickinson within the Pharmaceutical Systems business unit. In January 2015, he joined the global sales team of Datwyler Pharma Packaging as Key Account Manager Injection-Systems. Since June 2017, he has been acting in his current position as Global Head of Marketing and Product Management.
spacer
Massimo Mainetti at Datwyler
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

BEERSE, BELGIUM, May 18, 2020 The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations.[i] Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.[ii],[iii] Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), duration of response, as well as the safety profile of amivantamab,1 which were the basis of the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation granted earlier this year.[iv]
More info >>

White Papers

Interface: Drug Delivery Devices

Phillips-Medisize

A family is packing for its annual summer trek to the cottage by the lake. Along with fishing gear, sunscreen, and life vests, the checklist also includes another kind of life saver an autoinjector that delivers two doses of epinephrine to treat anaphylaxis, a severe and potentially lifethreatening allergic reaction.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement